The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori
Launched by HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY · Dec 29, 2021
Trial Information
Current as of August 02, 2025
Unknown status
Keywords
ClinConnect Summary
In China, the first-line therapy to treat Helicobacter pylori (Hp) consists of a bismuth-based proton pump inhibitor (PPI) and two antibiotics for 14 days.But, eradication has become less successful due to low compliance and high resistance to antibiotics. Therefore, it is necessary to develop new treatment strategies that increase the eradication rate and reduce adverse effects. Vonoprazan is a novel potassium-competitive acid blocker more effective in suppressing acid production than proton pump inhibitors (PPIs). Several studies previously suggested that vonoprazan containing antibiotic ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Helicobacter pylori infected patients comfirmed by 13C/14C UBT
- • age 18\~65
- Exclusion Criteria:
- • prior Hp eradication therapy including amoxicillin and clarithromycin
- • previous gastric resection
- • allergic to the drugs used in this study
- • previous use of proton pump inhibitors, bismuth, H2 receptor antagonist or antibiotics, probiotics within 4 weeks of the study
- • Patients who were pregnant or lactating
- • Patients taking NSAIDs, alcoholic or with other serious disease (e.g. hepatopathy, heart disease, nephropathy#diabete mellitus, hypertension...) effect the evaluation of this study
- • Can't express the complaint correctly
About Huazhong University Of Science And Technology
Huazhong University of Science and Technology (HUST) is a prestigious research university located in Wuhan, China, renowned for its commitment to advancing scientific knowledge and innovation in various fields, including medicine and healthcare. With a strong emphasis on interdisciplinary collaboration, HUST engages in cutting-edge clinical research aimed at improving patient outcomes and driving advancements in medical science. The university's clinical trial initiatives are supported by state-of-the-art facilities and a team of experienced researchers, making it a key player in the development of novel therapies and treatment strategies in the healthcare sector.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hubei, China
Patients applied
Trial Officials
Bin Cheng, Doctor
Principal Investigator
Tongji Hospital
si xiong, Doctor
Study Chair
Tongji Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials